Zynex Inc Stock: Chapter 11 Reorganization Cancels All Existing Shares, No Recovery for Prior Holders ISIN US98986M1036

Zynex Inc's common stock has been fully cancelled under its confirmed Chapter 11 reorganization plan, effective March 26, 2026, leaving prior shareholders with no recovery or remaining ownership.

The U.S. Bankruptcy Court for the Southern District of Texas confirmed the Third Amended Combined Disclosure Statement and Joint Chapter 11 Plan on March 19, 2026, triggering the cancellation of all outstanding common shares, equity awards, options, warrants, and related rights for no consideration.

As of: 28.03.2026

By Elena Harper, Senior Financial Editor at NorthStar Market Review: Zynex Inc, a medical device firm, navigated Chapter 11 restructuring amid payor disputes, reshaping its equity for North American investors.

Chapter 11 Plan Execution and Equity Cancellation

SEC Form 4 filings from directors Michael D. Cress, Joshua R. Disbrow, and Barry D. Michaels detail the disposition of their entire shareholdings back to Zynex Inc at zero value, directly tied to the bankruptcy plan's effectiveness.

Cress disposed of 12,499 restricted common shares and 82,501 common shares; Disbrow returned 12,499 restricted shares and 89,501 common shares; Michaels surrendered 80,001 common shares—all classified as issuer dispositions with no consideration.

This uniform cancellation across insider holdings confirms the plan's execution wiped out pre-petition equity comprehensively, a standard outcome in Chapter 11 cases where creditors take priority.

Post-effective date, Zynex operates as a reorganized debtor, with future disclosures expected to reveal any new capital structure, including potential issuance of fresh shares to creditors or new investors.

North American investors holding ZYXI prior to March 26 now own nothing in the reorganized entity, shifting focus to any distributions outside equity or recovery via litigation.

Background on Zynex's Medical Device Business and Restructuring Triggers

Zynex Inc developed and marketed non-invasive medical devices for pain management and rehabilitation, including electrotherapy systems targeting hospitals, outpatient clinics, and home use.

The company's restructuring stemmed from payor disputes, notably a Tricare payment suspension in early 2025, culminating in an agreement to forfeit over $85 million to resolve allegations.

Former executives faced indictments on January 21, 2026, for health care and securities fraud, accelerating the path to Chapter 11 and Nasdaq delisting.

These events underscore vulnerabilities in medical device firms reliant on government and insurance reimbursements, where compliance lapses can trigger cascading financial distress.

For the sector, Zynex's case highlights reimbursement risks amid heightened scrutiny on billing practices for durable medical equipment.

Securities Class Action Litigation Implications

A securities class action, Beidel v. Sandgaard et al., No. 1:26-cv-00714, filed in U.S. District Court for the District of Colorado, covers purchases from February 25, 2021, to December 15, 2025.

Law firms including Hagens Berman, Faruqi & Faruqi, and Levi & Korsinsky urge investors to seek lead plaintiff status by April 21, 2026.

Allegations center on misleading statements about revenue sources, tied to an oversupplying scheme inflating billings through unnecessary medical supply shipments.

While the bankruptcy plan bars equity recovery, litigation may pursue claims against former executives or insurers, offering a potential path for some loss recoupment.

North American retail investors, often hit hardest in such cases, should evaluate eligibility carefully, noting deadlines and proof requirements.

Investor Relevance for North American Shareholders

Pre-bankruptcy ZYXI holders in North America confront a complete equity loss, with no distributions under the plan, mirroring typical Chapter 11 outcomes for out-of-money equity.

The delisting to ZYXIQ symbol reflects distressed trading prior to cancellation, emphasizing the need for vigilance in small-cap medtech names.

Post-reorg, opportunities may arise if new shares distribute to creditors or via rights offerings, though details remain pending SEC filings.

U.S. and Canadian investors should monitor bankruptcy dockets and reorg disclosures for access to any residual value or new investment avenues.

Class action participation represents the primary recourse, potentially yielding modest recoveries depending on settlement outcomes.

Risks and Open Questions Post-Reorganization

Key uncertainties include the reorganized entity's capital structure, with no details yet on new common stock issuance or ownership distribution.

Ongoing litigation risks could impact operations or trigger further liabilities, even as the company emerges leaner.

Rebuilding payor relationships post-Tricare resolution and fraud indictments poses execution challenges in a competitive electrotherapy market.

North American investors must watch for operational updates, new equity filings, and litigation progress, avoiding unverified trading in over-the-counter remnants.

Broader sector risks—reimbursement cuts, compliance costs—amplify caution for similar firms.

What North American Investors Should Watch Next

Track SEC filings for post-effective plan disclosures on new securities and ownership, expected soon after March 26.

Monitor class action deadlines, with lead plaintiff motions due April 21, 2026, via firms like Hagens Berman.

Assess reorganized Zynex's path to relisting or private status, alongside quarterly operations amid medtech reimbursement trends.

Review personal holdings for proof of purchase during the class period to maximize litigation options.

Prioritize diversified medtech exposure over single-name distress plays.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.